You are here

BioXcel Therapeutics

Major readouts on the horizon for small developers

EP Vantage

Fri, 03/31/23 - 10:19 am

Aldeyra Therapeutics

Autolus Therapeutics

Bavarian Nordic

BioXcel Therapeutics

Editas Medicine

Mersana Therapeutics

NGM Biopharmaceuticals

Sutro BioPharma

Viking Therapeutics

BioXcel, keeping cards close to its chest, teases phase 2 Keytruda combination trial data drop

Fierce Biotech

Wed, 01/11/23 - 11:00 am

BioXcel Therapeutics

clinical trials

prostate cancer

Catalysts ahead for the smaller players

EP Vantage

Wed, 12/21/22 - 11:19 am

BioXcel Therapeutics

Calliditas Therapeutics

Esperion Therapeutics

Nektar Therapeutics

Oramed Pharmaceuticals

Pliant Therapeutics

Selecta Biosciences

Swedish Orphan Biovitrum

Vera Therapeutics

Viking Therapeutics

11 drugs granted FDA fast track designation in 2022

Beckers Hospital Review

Wed, 08/24/22 - 10:55 pm

Agios Pharmaceuticals

Bristol Myers Squibb

BioXcel Therapeutics

Mycovia Pharmaceuticals

Phathom Pharmaceuticals

Mitsubishi Tanabe Pharma

SIGA technologies

Alnylam Pharmaceuticals